Scholarlink

<p>Alzheimer’s disease (AD) is a chronic, multifactorial neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Pathological hallmarks include extracellular amyloid-β (Aβ) deposition and intracellular neurofibrillary tangles (NFTs) in brain cells, which drive neuronal degeneration and dementia. Current drugs provide only symptomatic relief, with limited efficacy and adverse side effects, underscoring the need for novel therapeutics. In this study, phytochemicals from <i>Curcuma longa</i> were screened for drug-likeness using ADME and pharmacokinetic analyses, identifying curcuminoids—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—as bioavailable candidates. Molecular docking (MD) revealed strong binding affinities for AD therapeutic targets, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), glycogen synthase kinase-3β (GSK-3β), β-secretase, and γ-secretase (− 11.07 to − 22.70&#xa0;kcal/mol), suggesting multi-target inhibitory potential. MD simulations (100 ns) demonstrated structural stability, with demethoxycurcumin showing the lowest RMSD values (~ 0.13–0.18&#xa0;nm for AChE). MM-GBSA free energy calculations confirmed favorable binding (ΔG_binding − 23.35&#xa0;kcal/mol for β-secretase–demethoxycurcumin and − 21.68&#xa0;kcal/mol for BuChE–demethoxycurcumin). In vivo validation using an Aβ<sub>42</sub>-expressing <i>Drosophila</i> model showed dose-dependent reductions in cholinesterase activity (60–75% at 5&#xa0;mg/mL, <i>p</i> &lt; 0.05), suppression of AD-associated proteins (Aβ<sub>42</sub>: ~50–60%; BACE1: ~30–40%; GSK-3β: ~50–60%; KEAP1: ~30–40%), lifespan extension (27.98 → 38.66 days, <i>p</i> &lt; 0.001), and improved motor activity (climbing index ~ 0.70 → ~0.90–1.00, <i>p</i> &lt; 0.001). Collectively, these findings highlight curcuminoids as a promising multi-target-directed ligand for AD therapy, warranting further validation in higher-order animal models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroprotective curcuminoids from Curcuma longa as multi-target-directed ligand therapeutics for Alzheimer’s disease: an integrated in silico and in vivo approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Reshma Ramarajan,
  • Hulikal Shivashankara Santosh Kumar,
  • Deepthi Sreepathi,
  • Manish Kumar,
  • Gollapalli Pavan,
  • Tamizh Selvan Gnanasekaran,
  • Hunasanahally Puttaswamygowda Gurushankara

摘要

Alzheimer’s disease (AD) is a chronic, multifactorial neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Pathological hallmarks include extracellular amyloid-β (Aβ) deposition and intracellular neurofibrillary tangles (NFTs) in brain cells, which drive neuronal degeneration and dementia. Current drugs provide only symptomatic relief, with limited efficacy and adverse side effects, underscoring the need for novel therapeutics. In this study, phytochemicals from Curcuma longa were screened for drug-likeness using ADME and pharmacokinetic analyses, identifying curcuminoids—curcumin, demethoxycurcumin, and bisdemethoxycurcumin—as bioavailable candidates. Molecular docking (MD) revealed strong binding affinities for AD therapeutic targets, including acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), glycogen synthase kinase-3β (GSK-3β), β-secretase, and γ-secretase (− 11.07 to − 22.70 kcal/mol), suggesting multi-target inhibitory potential. MD simulations (100 ns) demonstrated structural stability, with demethoxycurcumin showing the lowest RMSD values (~ 0.13–0.18 nm for AChE). MM-GBSA free energy calculations confirmed favorable binding (ΔG_binding − 23.35 kcal/mol for β-secretase–demethoxycurcumin and − 21.68 kcal/mol for BuChE–demethoxycurcumin). In vivo validation using an Aβ42-expressing Drosophila model showed dose-dependent reductions in cholinesterase activity (60–75% at 5 mg/mL, p < 0.05), suppression of AD-associated proteins (Aβ42: ~50–60%; BACE1: ~30–40%; GSK-3β: ~50–60%; KEAP1: ~30–40%), lifespan extension (27.98 → 38.66 days, p < 0.001), and improved motor activity (climbing index ~ 0.70 → ~0.90–1.00, p < 0.001). Collectively, these findings highlight curcuminoids as a promising multi-target-directed ligand for AD therapy, warranting further validation in higher-order animal models.